Caribou and Integrated DNA Technologies, Inc. (IDT), a manufacturer of synthetic oligonnucleotide-based synthetic technologies for genomic applications, entered into a non-exclusive licensing agreement in 2016 under which Caribou granted IDT intellectual property rights to Caribou for the marketing of CRISPR-Cas9 reagents. Reagents are sold by IDT on a limited-label license and Caribou receives royalties on reagents sold by IDT. IDT`s CRISPR-Cas9 reagents are used by clients who conduct biological research in a wide range of scientific fields such as drug discovery, plant biology and genomics, and enable researchers to treat genomic DNA accurately and effectively. See the press release. According to a press release dated 1 December 2020, Vivlion already owns the exclusive license of Frankfurt University`s exclusive 3Cs technology for the production of next-generation CRISPR/Cas gRNA libraries. With the license of ERS Genomics, Vivlion is now able to offer research and development reagents and screening services to customers around the world. In 2020, Caribou and Danisco US Inc. entered into a non-exclusive license, under which Caribou Danisco granted intellectual property rights under certain CRISPR-Cas9 intellectual property rights controlled by Caribou for Danisco`s COVID project, a research and development program related to the rapid and large-scale production of potential antibody therapies for the COVID-19 pandemic. Caribou and Oxford Nanopore Technologies Ltd (ONT), a British company, entered into a non-exclusive licensing agreement in August 2019 under which Caribou ONT granted global rights for the use of CRISPR-Cas9 for nanopore sequencing and nanoporendetage for research and diagnostic applications. ONT aims to disrupt the paradigm of biological analysis by developing a high-performance, accessible and easy-to-use DNA/RNA sequencing technology. The license also includes the right to market CRISPR-Cas9 Nanopore detection and detection products and services.

These products and services are sold by ONT on the basis of a license for the use of a limited label, and Caribou receives royalties on sales and is authorized for certain sales stones. The creation of your mouse variety or other product (the “licensed product”) using CRISPRCas9 technology is provided by the Jackson Laboratory (“Jackson”) as part of a licensing agreement with the Broad Institute, Inc. (“Broad”), which contains certain restrictions and obligations. By purchasing this service, you agree, the limited licensee, to be bound to the limited license listed below. Other capitalized terms are defined below. CRISPR Therapeutics Investor Contact: Susan Kim – 1 617-307-7503 Caribou granted the Jackson Laboratory (JAX) the non-exclusive global right to use the intellectual property of Caribous CRISPR-Cas9 for the manufacture of genetically modified mice for research purposes. Caribous` CRISPR-Cas9 gene editing technology can accurately target and cut DNA to produce precise and controllable genome modifications, which can be applied by JAX to create mouse models that summarize human diseases so that researchers can find better treatments more quickly.